Current version snapshot

Not FDA-approved↗Safety records↗↗

Current · version 3: Semax↗

A synthetic seven-amino-acid peptide that is not FDA-approved in the United States. FDA’s 2026 review found only small, incompletely reported human studies.↗

This immutable URL preserves the current public version.
The canonical profile remains the primary reading view. Read the canonical profile.
Update · November 14, 2026

We added a plain-language reader guide with cited answers, re-checked FDA’s Semax briefing, and added HHS’s October 30, 2026 draft enforcement-discretion policy, which lists Semax free base. FDA has not issued a final 503A rule. 156

What this version reported

FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. An October 30, 2026 HHS draft enforcement-discretion policy lists Semax free base among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions; it does not make Semax an FDA-approved drug.↗↗↗↗

Organizations named in cited records:
  • U.S. Food and Drug Administration↗↗
  • U.S. Department of Health and Human Services↗

Reader guide in this version

Key takeaway

Semax is a synthetic seven-amino-acid peptide modeled on a fragment of the hormone ACTH. It is a registered drug in Russia, and many of the studies FDA found were published only in Russian.1 It is not an FDA-approved drug, and FDA’s 2026 evaluation found no United States Pharmacopeia or European Pharmacopoeia monograph for it.1 Human data are limited to small, mostly uncontrolled or incompletely reported studies. FDA found insufficient evidence that it works for the uses it evaluated and insufficient information to describe its safety.1 FDA staff recommended against adding Semax to the list of substances pharmacies may use in compounding, but an October 2026 HHS draft policy lists it among six peptides for which HHS says it does not intend to take enforcement action against licensed compounders who meet its conditions while FDA’s rulemaking continues.1,5,6

At a glance

What it is
A synthetic peptide of seven amino acids, designed from a fragment of adrenocorticotropic hormone (ACTH) without that hormone’s hormonal effects.1
FDA status
Not FDA-approved. FDA staff recommended in May 2026 against adding Semax to the 503A compounding list, and FDA has not issued a final rule. Under an October 30, 2026 HHS draft enforcement-discretion policy, Semax free base is one of six listed peptides; HHS says it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians that compound it under the policy’s conditions.1,5,6
Human evidence
Small studies and meeting abstracts, mostly without a control group. The one pain study FDA reviewed in detail found that Semax did not resolve pain for most participants.1
Evidence strength
Limited human data

What is Semax?

Semax is a synthetic peptide made of seven amino acids. FDA’s briefing describes it as an analog of a fragment of adrenocorticotropic hormone (ACTH) that lacks the hormone’s effects on the adrenal glands and skin pigment but keeps effects on the nervous system.1

Semax is a registered drug in Russia. There is no monograph for it in the European, Japanese or International Pharmacopoeia.1

FDA could not determine how widely Semax has been used in U.S. compounding. It found Semax widely marketed by wellness and concierge clinics and online retailers for conditions ranging from anxiety and memory to stroke and nerve damage, often without saying whether products were compounded.1

How is Semax thought to work?

How Semax works is poorly understood. In rodents it has been reported to protect nerve cells, reduce clotting, relieve pain, and produce antidepressant-like and anti-anxiety-like effects.1

FDA flags two concerns from these studies. Semax’s possible anti-clotting effect raises a bleeding risk, and in mice it increased the brain’s dopamine response to amphetamine, a pattern FDA associates with drugs of abuse.1

FDA found no studies in people showing how Semax is absorbed or handled by the body.1

What do human studies show?

FDA evaluated Semax for reduced blood flow to the brain (cerebral ischemia), migraine and trigeminal neuralgia, and concluded there is insufficient evidence that it works for any of them.1

The only study FDA reviewed in detail for pain was a small 1996 study without a control group or blinding. A minority of migraine patients reported relief, and the authors themselves concluded that Semax did not show pain-relieving activity on its own in trigeminal neuralgia.1

For cerebral ischemia, FDA found only a meeting abstract that did not report clinical outcomes. Other studies were published in Russian without full English versions, so FDA did not consider them.1

Across the reports FDA found, Semax had been given to between about 100 and 115 adults and to 451 children. Most reports did not discuss side effects, and one reported none.1

FDA’s adverse-event database search through December 2025 found one consumer report, of eye pain and burning with hospitalization in 2024, after using a Semax product.1

What the evidence base contains

  • Small, short, or incompletely reported human study A 1996 study without a control group or blinding in 37 adults with migraine or facial nerve pain. Four of 12 migraine patients reported that their headache stopped, and patients with typical trigeminal neuralgia showed no change in pain.1
  • Small, short, or incompletely reported human study A 2002 meeting abstract on people with chronic reduced blood flow to the brain that did not report the number of patients or clinical outcomes.1
  • Small, short, or incompletely reported human study Other reports FDA found in healthy adults, adults with peptic ulcer, and children with depression or tics. Several are meeting abstracts, most did not discuss side effects, and in some Semax was given alongside other treatments.1
  • Animal or laboratory research Rodent studies reporting nerve-protective, anti-clotting, pain-relieving and antidepressant-like effects through mechanisms FDA describes as poorly understood.1

Evidence-strength label: Limited human data. How this label is assigned

Is Semax FDA-approved?

No. FDA’s May 2026 evaluation states that neither Semax free base nor Semax acetate is a component of an FDA-approved drug and that there is no United States Pharmacopeia monograph for either.1

Under section 503A of the federal drug law, the list of bulk substances that pharmacies can use in compounding, known as the 503A bulks list, is being developed through FDA rulemaking.5

FDA staff evaluated both forms of Semax for that list and recommended against adding either. They cited missing chemical characterization data, insufficient evidence of effectiveness, safety concerns including bleeding risk and possible immune reactions, and existing FDA-approved treatments for most of these conditions.1

FDA’s compounding safety-risk page, last updated April 22, 2026, lists Semax among substances whose nominations were withdrawn and says FDA lacks enough information to know whether it would cause harm in people.3

HHS’s policy document states that Semax was in FDA’s Category 2, the group of nominated substances that may present significant safety risks, from September 29, 2023 until April 22, 2026, and that neither change altered its status under section 503A.3,6

FDA’s Pharmacy Compounding Advisory Committee discussed Semax on July 24, 2026. HHS’s policy document states that the committee voted in favor of both forms, while FDA’s drug-review center had recommended against listing either form. FDA’s own meeting page, last updated August 6, 2026, lists no vote record.1,2,6

On October 30, 2026, HHS published notice of a draft policy saying it does not intend to take enforcement action against licensed pharmacies, federal facilities or physicians compounding with the peptide substances listed in the policy’s appendix while the 503A list is developed. HHS calls it an interim policy, says it is not binding, and says it may be revisited if safety or quality problems arise.5,6

Appendix A of the policy lists six peptides: BPC-157, Epitalon, KPV, MOTS-c, Semax and TB-500. For Semax, unlike the other five, the policy covers only the free-base form. It applies only when its conditions are met, including a patient-specific prescription, a single listed active ingredient, bulk substance from an FDA-registered facility with a certificate of analysis, and reporting of serious adverse events to FDA.6

HHS and FDA staff weigh the same record differently. HHS’s policy document says newer certificates supply the quality test results FDA staff found missing, that use is now documented, and that the human record FDA staff compiled covers several hundred people with no reported adverse outcome. FDA staff had concluded that the clinical information was insufficient to characterize Semax’s safety.1,6

The policy does not make Semax an FDA-approved drug and is not an FDA rule. HHS notes that FDA does not review compounded drugs for safety, effectiveness or quality before they are marketed.5,6

Timeline

  1. A small study of Semax in adults with migraine and facial nerve pain is published, the main pain study FDA later reviewed.1
  2. Semax is placed in FDA’s Category 2 of nominated compounding substances that may present significant safety risks, according to HHS’s policy document.6
  3. A Federal Register notice announces the July advisory-committee meeting that will discuss Semax and opens a public comment docket.4
  4. Semax leaves Category 2, according to HHS’s policy document. FDA’s compounding safety-risk page, as last updated that day, lists it among withdrawn nominations.3,6
  5. FDA staff date their evaluation recommending that Semax not be added to the 503A bulks list.1
  6. FDA’s Pharmacy Compounding Advisory Committee discusses Semax.2
  7. HHS publishes notice of a draft enforcement-discretion policy whose Appendix A lists Semax among six peptide substances used in compounding.5,6

What is still unknown?

Whether Semax benefits people for any condition: FDA found no adequately reported controlled trial.1

Its safety, including bleeding risk and abuse potential, and how it is absorbed in people.1

What is in products sold under the name: FDA notes that the free-base and acetate forms are distinct substances and that the studies it found did not say which form they used.1

Whether FDA’s rulemaking will add Semax to the 503A list, and how long the October 2026 HHS interim policy will remain in place, remained unresolved in the sources reviewed through November 14, 2026.1,5,6

Sources for this version

  1. 1
    FDA briefing document for Semax ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  2. 2
    July 23-24, 2026 Pharmacy Compounding Advisory Committee meeting ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  3. 3
    Certain bulk drug substances for use in compounding that may present significant safety risks ↗

    U.S. Food and Drug Administration · Official source · Source checked November 14, 2026

  4. 4
    Federal Register notice 2026-07361 · published 2026-04-16 · Pharmacy Compounding Advisory Committee; Notice of Meeting; Establishment of a Public Docket; Request for Comments-Bulk Drug Substances Nominated for Inclusion on the Section 503A Bulk Drug Substances List ↗

    Federal Register via GovInfo · Official source · Source checked August 21, 2026

  5. 5
    Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances · notice of availability · 91 FR 68526 · October 30, 2026 ↗

    Federal Register · U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026

  6. 6
    HHS Enforcement Discretion Policy Regarding 503A Compounding Using Certain Peptide Bulk Drug Substances, with Appendix A (list of peptides) and Appendix B (identities and justifications) ↗

    U.S. Department of Health and Human Services · Official source · Source checked November 14, 2026